Efficacy of once-daily (o.d.) indacaterol/glycopyrronium/mometasone (IND/GLY/MF) vs free combination of twice-daily salmeterol/fluticasone (SAL/FLU) & o.d. tiotropium with respect to age, age at asthma-onset & BMI at baseline: ARGON subgroup analysis

Conclusion: The patient characteristics analysed (age, age of asthma onset & BMI) do not significantly impact positive outcomes when using single inhaler o.d. IND/GLY/MF vs free combination of twice daily (b.i.d.) SAL/FLU & o.d. TIO. Therefore, treatment personalisation in terms of patient preference (e.g., convenience of o.d. vs b.i.d. regimen, single inhaler, device type) would be more appropriate.

Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Van Zyl-Smit, R., Lawrence, D., Mezzi, K., Brittain, D., Jaumont, X., Gessner, C. Tags: 05.01 - Airway pharmacology and treatment Source Type: research